Bloomberg: IPOX® Analyst Muehlbauer Discusses Investor Selectivity Amid European IPO Market Turmoil

A recent Bloomberg article highlights the challenging environment facing recent European IPOs. The piece examines the performance of major 2024 listings, noting that while some like Galderma Group AG remain above their issue price, others including CVC Capital Partners Plc, Zabka Group AG, Puig Brands SA, and Douglas AG have faltered amidst market volatility. The report also observes that European IPO deal volume in early 2025 is significantly lower compared to the previous year, reflecting the current market uncertainty.

In the article, IPOX® Research Analyst Dr. Lukas Muehlbauer was interviewed by Bloomberg, providing insights into the prevailing investor sentiment. He commented on the heightened caution in the market, stating, "Investors are more selective to see if quality deals come up and the fundamentals are matching." This underscores the increased scrutiny IPO candidates face as market participants prioritize strong fundamentals and proven track records in the current climate.

The article was published by Bloomberg on April 9, 2025.

Bloomberg Terminal subscribers can read the full article here: https://blinks.bloomberg.com/news/stories/SUENGGDWRGG0